NCT01609062
MPS IVA, Morquio A Syndrome, Mucopolysaccharidosis IVA
The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc. and has not been edited.
The primary objective of this study was to evaluate the safety of a 2.0 mg/kg/week and a 4.0 mg/kg/week of BMN 110 in patients with Morquio A syndrome for up to 196 weeks. Secondary objectives were to investigate the effect of the two doses on exercise capacity for up to 196 weeks. In addition, the pharmacokinetic (PK) parameters of both doses of BMN 110 was assessed.
All
From 7 Years
No
BMN 110, BMN 110
Phase 2
Interventional
25
2012-04
2016-02-01
Oakland, California, United States
Chicago, Illinois, United States
New York, New York, United States
Houston, Texas, United States
Calgary, Alberta, Canada
Toronto, Ontario, Canada
Montreal, Quebec, Canada
Sherbrook, Quebec, Canada
Hamburg, , Germany
Belfast, Northern Ireland, United Kingdom
Manchester, , United Kingdom
*required fields
"*" indicates required fields